New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - sotalol hydrochloride 160mg - tablet - 160 mg - active: sotalol hydrochloride 160mg excipient: calcium hydrogen phosphate magnesium stearate maize starch povidone purified talc sodium starch glycolate - sotalol hydrochloride is indicated for use in the prevention and treatment of supraventricular and ventricular arrhythmias.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - sotalol hydrochloride 80mg - tablet - 80 mg - active: sotalol hydrochloride 80mg excipient: calcium hydrogen phosphate magnesium stearate maize starch povidone purified talc sodium starch glycolate - sotalol hydrochloride is indicated for use in the prevention and treatment of supraventricular and ventricular arrhythmias.

Den Europæiske Union - engelsk - myHealthbox

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/850 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets

Den Europæiske Union - engelsk - myHealthbox

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/1,000 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets

Malta - engelsk - Malta Medicines Authority

lab. chimico farmaceutico a sella s.r.l via vicenza 67, schio, italy - cetylpyridinium chloride - lozenge - cetylpyridinium chloride 3 mg - throat preparations

Malta - engelsk - Malta Medicines Authority

dompe farmaceutici spa via san martino 12, 20122, milan, italy - carbocisteine - syrup - carbocisteine 2.7 g - cough and cold preparations

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antithrombotic agents - brilique, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (acs) ora history of myocardial infarction (mi) and a high risk of developing an atherothrombotic eventbrilique, co-administered with acetyl salicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, type 2 - drugs used in diabetes - bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:metforminsulphonylureathiazolidinedionemetformin and sulphonylureametformin and thiazolidinedionein adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

otsuka novel products gmbh - delamanid - tuberculosis, multidrug-resistant - antimycobacterials - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.